Lafora disease: Epidemiology, pathophysiology and management

CNS Drugs

Volumn 24, Issue 7, 2010, Pages 549-561

  Monaghan, Thomas S ^a   Delanty, Norman ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Antiepileptic drugs, therapeutic use; Epilepsy; Metabolic disorders; Myoclonic epilepsies.

Indexed keywords

5 HYDROXYTRYPTOPHAN; ACETYLCYSTEINE; CARBOHYDRATE; CLONAZEPAM; ETIRACETAM; MIDAZOLAM; PHENOBARBITAL; PIRACETAM; PROTEIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

BRAIN BIOPSY; CARBOHYDRATE METABOLISM; CELL INCLUSION; CLINICAL FEATURE; CLINICAL TRIAL; DEMENTIA; DIET THERAPY; DRUG MEGADOSE; EPILEPTIC STATE; GENETIC ANALYSIS; HUMAN; MYOCLONUS; MYOCLONUS EPILEPSY; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; TONIC CLONIC SEIZURE;

ANTICONVULSANTS; BRAIN; CARRIER PROTEINS; DIAGNOSIS, DIFFERENTIAL; ELECTROENCEPHALOGRAPHY; HUMANS; LAFORA DISEASE; MAGNETIC RESONANCE IMAGING; MUTATION; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR;

EID: 77953308953     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11319250-000000000-00000     Document Type: Review

References (123)

1. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005 Apr; 4 (4): 239-248
2. Nanduri AS, Kaushal N, Clusmann H, et al. The maestro don Gonzalo Rodriguez-Lafora. Epilepsia 2008 Jun; 49 (6): 943-947
3. Lafora G, Glueck B. Beitrag zur histopathologie der myoklonischen epelepsie. Z Gesante Neurol Psychiatr 1911; 6: 1-14
4. Franceschetti S, Gambardella A, Canafoglia L, et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia 2006 Mar; 47 (3): 640-643
5. Singh S, Suzuki T, Uchiyama A, et al. Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population. J Human Genet 2005; 50 (7): 347-352
6. Acharya JN, Satischandra P, Asha T, et al. Lafora's disease in south India: a clinical, electrophysiologic, and pathologic study. Epilepsia 1993 May-Jun; 34 (3): 476-487
7. Gomez-Abad C, Afawi Z, Korczyn AD, et al. Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation. Epilepsia 2007 May; 48 (5): 1011-1014
8. Solis MV. [Lafora disease and founder effect in a small neotropical locality]. Rev Biol Trop 2000 Jun-Sep; 48 (2-3): 703-706
9. Baykan B, Striano P, Gianotti S, et al. Late-onset and slow-progressing Lafora disease in four siblings with EPM2B mutation. Epilepsia 2005 Oct; 46 (10): 1695-1697
10. Messouak O, Yahyaoui M, Benabdeljalil M, et al. [Late discovery of Lafora disease: a family study]. Rev Neurol 2002 Jan; 158 (1): 74-76
11. Footitt DR, Quinn N, Kocen RS, et al. Familial Lafora body disease of late onset: report of four cases in one family and a review of the literature. J Neurol 1997 Jan; 244 (1): 40-44
12. Kaufman MA, Dwork AJ, Willson NJ, et al. Late-onset Lafora's disease with typical intraneuronal inclusions. Neurology 1993 Jun; 43 (6): 1246-1248
13. Mouren MC, Roger J. Recent data on Lafora disease: apropos of 17 cases. Arch Fr Pediatr 1979 Mar; 36 (3): 268-277
14. Lopez-Meza EG, Cerda-Tellez F, Alanis-Guevara IM, et al. Non-convulsive epileptic status associated with Lafora disease: two case reports. Rev Neurol 2003 Nov 16-30; 37 (10): 945-947
15. Ramachandran N, Girard JM, Turnbull J, et al. The autosomal recessively inherited progressive myoclonus epilepsies and their genes. Epilepsia 2009 May; 50 Suppl. 5: 29-36
16. Pichiecchio A, Veggiotti P, Cardinali S, et al. Lafora disease: spectroscopy study correlated with neuro-psychological findings. Eur J Paediatr Neurol 2008 Jul; 12 (4): 342-347
17. Villanueva V, Alvarez-Linera J, Gomez-Garre P, et al. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease. Epilepsia 2006 Apr; 47 (4): 788-792
18. Cukiert A, Vilela MM, Scapolan HB, et al. Mental deterio-ration in Lafora's disease. Arq Neuropsiquiatr 1990 Jun; 48 (2): 236-240
19. Kumada S, Kubota M, Hayashi M, et al. Fixation-sensitive myoclonus in Lafora disease. Neurology 2006 May 23; 66 (10): 1574-1576
20. Andrade DM, del Campo JM, Moro E, et al. Nonepileptic visual hallucinations in Lafora disease. Neurology 2005 Apr 12; 64 (7): 1311-1312
21. Rustam H, Hamdi T, Witri S. Progressive familial myo-clonus epilepsy. J Neurol Neurosurg Psychiatry 1975 Sep; 38 (9): 845-848
22. de Graaf AS, Ancker E, Rutherfoord GS, et al. Lafora-body disease with optic atrophy, macular degeneration and cardiac failure. J Neurol Sci 1989 Oct; 93 (1): 69-84
23. Gomez-Garre P, Gutierrez-Delicado E, Gomez-Abad C, et al. Hepatic disease as the first manifestation of progressive myoclonus epilepsy of Lafora. Neurology 2007 Apr 24; 68 (17): 1369-1373
24. Elliott EJ, Talbot IC, Pye IF, et al. Lafora disease: a pro-gressive myoclonus epilepsy. J Pediatr Child Health 1992 Dec; 28 (6): 455-458
25. Oksel F, Tekgul H, Genc S, et al. A case of Lafora's disease associated with cardiac arrhythmia. J Child Neurol 1999 Nov; 14 (11): 745-746
26. Tinuper P, Plazzi G, Monari L, et al. Arylsulfatase A pseudodeficiency and Lafora bodies in a patient with progressive myoclonic epilepsy. Epilepsia 1994 Mar-Apr; 35 (2): 332-335
27. Bertagnolio B, Girotti F, Pelucchetti D, et al. Myoclonic epilepsy of Lafora and arylsulphatase A deficiency in the same patient. J Inherit Metab Dis 1989; 12 (4): 458-466
28. Wick R, Byard RW. Mechanisms of unexpected and/or sudden death in Lafora disease. Forensic Sci Int 2006 Nov 10; 163 (1-2): 144-147
29. Scelsi R, Mazzella GL, Lombardi M. Myoclonus epilepsy with cerebellar Lafora bodies: report of a case. J Neurol Neurosurg Psychiatry 1976 Apr; 39 (4): 357-361
30. Tagliabracci VS, Turnbull J, Wang W, et al. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Nat Acad Sci USA 2007 Dec 4; 104 (49): 19262-19266
31. Lohi H, Ianzano L, Zhao XC, et al. Novel glycogen syn-thase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum Mol Genet 2005 Sep 15; 14 (18): 2727-2736
32. Garyali P, Siwach P, Singh PK, et al. The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system. Hum Mol Genet 2009 Feb 15; 18 (4): 688-700
33. Nikaido T, Austin J, Stukenbrok H. Studies in myoclonus epilepsy: 3. The effects of amylolytic enzymes on the ultrastructure of Lafora bodies. J Histochem Cytochem 1971 Jun; 19 (6): 382-385
34. Busard HL, Renier WO, Gabreels FJ, et al. Lafora disease: a quantitative morphological and biochemical study of the cerebral cortex. Clin Neuropathol 1987 Jan-Feb; 6 (1): 1-6
35. Canafoglia L, Ciano C, Panzica F, et al. Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease. Neurology 2004 Dec 28; 63 (12): 2309-2315
36. Tsuda H, Katsumi Y, Nakamura M, et al. Cerebral blood flow and metabolism in Lafora disease. Rinsho Shinkeigaku 1995 Feb; 35 (2): 175-179
37. Minassian BA, Lee JR, Herbrick JA, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 1998 Oct; 20 (2): 171-174
38. Serratosa JM, Delgado-Escueta AV, Posada I, et al. The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q. Hum Mol Genet 1995 Sep; 4 (9): 1657-1663
39. Lehesjoki AE, Koskiniemi M, Sistonen P, et al. Localiza-tion of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proc Nat Acad Sci U S.A 1991 May 1; 88 (9): 3696-3699
40. Ganesh S, Agarwala KL, Amano K, et al. Regional and developmental expression of Epm2a gene and its evolutionary conservation. Biochem Biophys Res Commun 2001 May 25; 283 (5): 1046-1053
41. Minassian BA, Ianzano L, Delgado-Escueta AV, et al. Identification of new and common mutations in the EPM2A gene in Lafora disease. Neurology 2000 Jan 25; 54 (2): 488-490
42. Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat 2009 May; 30 (5): 715-723
43. Gomez-Garre P, Sanz Y, Rodriguez De Cordoba SR, et al. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions. Eur J Hum Genet 2000 Dec; 8 (12): 946-954
44. Ganesh S, Tsurutani N, Suzuki T, et al. The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies. Biochem Biophys Res Commun 2004 Jan 23; 313 (4): 1101-1109
45. Dubey D, Ganesh S. Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum Mol Genet 2008 Oct 1; 17 (19): 3010-3020
46. Ianzano L, Young EJ, Zhao XC, et al. Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy. Hum Mutat 2004 Feb; 23 (2): 170-176
47. Liu Y, Wang Y, Wu C, et al. Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling. J Biol Chem 2006 Nov 17; 281 (46): 34768-34774
48. Ganesh S, Delgado-Escueta AV, Suzuki T, et al. Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum Mol Genet 2002 May 15; 11 (11): 1263-1271
49. Annesi G, Sofia V, Gambardella A, et al. A novel exon 1 mutation in a patient with atypical Lafora progressive myoclonus epilepsy seen as childhood-onset cognitive deficit. Epilepsia 2004 Mar; 45 (3): 294-295
50. Chan EM, Omer S, Ahmed M,et al. Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 2004 Aug 10; 63 (3): 565-567
51. Delgado-Escueta AV. Advances in lafora progressive myoclonus epilepsy. Curr Neurol Neurosci Rep 2007 Sep; 7 (5): 428-433
52. Fernandez-Sanchez ME, Criado-Garcia O, Heath KE, et al. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet 2003 Dec 1; 12 (23): 3161-3171
53. Wang W, Lohi H, Skurat AV, et al. Glycogen metabolism in tissues from a mouse model of Lafora disease. Arch Biochem Biophys 2007 Jan 15; 457 (2): 264-269
54. Chan EM, Bulman DE, Paterson AD, et al. Genetic map-ping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet 2003 Sep; 40 (9): 671-675
55. Chan EM, Young EJ, Ianzano L, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 2003 Oct; 35 (2): 125-127
56. Gentry MS, Worby CA, Dixon JE. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Nat Acad Sci USA 2005 Jun 14; 102 (24): 8501-8506
57. Gomez-Abad C, Gomez-Garre P, Gutierrez-Delicado E, et al. Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology 2005 Mar 22; 64 (6): 982-986
58. Singh S, Sethi I, Francheschetti S, et al. Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy. J Med Genet 2006 Sep; 43 (9): e48
59. Traore M, Landoure G, Motley W, et al. Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease. Neurogenetics 2009 Oct; 10 (4): 319-323
60. Ianzano L, Zhang J, Chan EM, et al. Lafora progressive myoclonus epilepsy mutation database: EPM2A and NHLRC1 (EPM2B) genes. Hum Mutat 2005 Oct; 26 (4): 397
61. Boccella P, Striano P, Zara F, et al. Bioptically demon-strated Lafora disease without EPM2A mutation: a clinical and neurophysiological study of two sisters. Clin Neurol Neurosurg 2003 Dec; 106 (1): 55-59
62. Minassian BA. Lafora's disease: towards a clinical, patho-logic, and molecular synthesis. Pediatr Neurol 2001 Jul; 25 (1): 21-29
63. Ponsford S, Pye IF, Elliot EJ. Posterior paroxysmal dis-charge: an aid to early diagnosis in Lafora disease. J Royal Soc Med 1993 Oct; 86 (10): 597-599
64. Yen C, Beydoun A, Drury I. Longitudinal EEG studies in a kindred with Lafora disease. Epilepsia 1991 Nov-Dec; 32 (6): 895-899
65. Kobayashi K, Iyoda K, Ohtsuka Y, et al. Longitudinal clinicoelectrophysiologic study of a case of Lafora disease proven by skin biopsy. Epilepsia 1990 Mar-Apr; 31 (2): 194-201
66. Panzica F, Canafoglia L, Franceschetti S, et al. Movement-activated myoclonus in genetically defined progressive myoclonic epilepsies: EEG-EMG relationship estimated using autoregressive models. Clin Neurophysiol 2003 Jun; 114 (6): 1041-1052
67. Orizaola P, Calleja J. Progressive study of EEG and evoked potentials in Lafora disease. Rev Neurol 1998 Jul; 27 (155): 81-85
68. Acharya JN, Satishchandra P, Shankar SK. Familial pro-gressive myoclonus epilepsy: clinical and electrophysiologic observations. Epilepsia 1995 May; 36 (5): 429-434
69. Aguglia U, Farnarier G, Tinuper P, et al. Brainstem audi-tory evoked responses in Lafora disease. Clin Electro-encephalogr 1985 Oct; 16 (4): 202-207
70. Tseng CF, Ho CS, Chiu NC, et al. Lafora disease and congenital generalized lipodystrophy: a case report. Kaohsiung J Med Sci 2009 Dec; 25 (12): 663-668
71. Canafoglia L, Ciano C, Visani E, et al. Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease. Epilepsy Res May; 89 (2-3): 232-237
72. Verrotti A, Salusti B, Trotta D, et al. Epilepsy evaluation by electroencephalography and magnetoencephalography in Lafora-body disease: a case report. Acta Paediatr 2003 Oct; 92 (10): 1218-1222
73. Striano P, Ackerley CA, Cervasio M, et al. 22-year-old girl with status epilepticus and progressive neurological symptoms. Brain Pathol 2009 Oct; 19 (4): 727-730
74. Altindag E, Kara B, Baykan B, et al. MR spectroscopy findings in Lafora disease. J Neuroimaging 2009 Oct; 19 (4): 359-365
75. Kato Z, Yasuda K, Ishii K, et al. Glucose metabolism evaluated by positron emission tomography in Lafora disease. Pediatr Int 1999 Dec; 41 (6): 689-692
76. Jennesson M, Milh M, Villeneuve N, et al. Posterior glu-cose hypometabolism in Lafora disease: early and late FDG-PET assessment. Epilepsia Apr; 51 (4): 708-711
77. Carpenter S, Karpati G. Sweat gland duct cells in Lafora disease: diagnosis by skin biopsy. Neurology 1981 Dec; 31 (12): 1564-1568
78. Carpenter S, Karpati G, Andermann F, et al. Lafora's disease: peroxisomal storage in skeletal muscle. Neurology 1974 Jun; 24 (6): 531-538
79. Goebel HH. Extracerebral biopsies in neurodegenerative diseases of childhood. Brain Dev 1999 Oct; 21 (7): 435-443
80. Busard HL, Gabreels-Festen AA, Renier WO, et al. Axilla skin biopsy: a reliable test for the diagnosis of Lafora's disease. Ann Neurol 1987 Jun; 21 (6): 599-601
81. O'Shea AM, Wilson GJ, Ling SC, et al. Lafora-like ground-glass inclusions in hepatocytes of pediatric patients: a report of two cases. Pediatr Dev Pathol 2007 Sep-Oct; 10 (5): 351-357
82. Andrade DM, Ackerley CA, Minett TS, et al. Skin biopsy in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology 2003 Dec 9; 61 (11): 1611-1614
83. Nishimura RN, Ishak KG, Reddick R, et al. Lafora disease: diagnosis by liver biopsy. Ann Neurol 1980 Oct; 8 (4): 409-415
84. Baumann RJ, Kocoshis SA, Wilson D. Lafora disease: liver histopathology in presymptomatic children. Ann Neurol 1983 Jul; 14 (1): 86-89
85. Al Otaibi SF, Minassian BA, Ackerley CA, et al. Unusual presentation of Lafora's disease. J Child Neurol 2003 Jul; 18 (7): 499-501
86. Tuzun E, Gurses C, Baykan B, et al. Lafora body-like in-clusions in a case of progressive myoclonic ataxia associated with coeliac disease. Eur Neurol 2001; 46 (3): 157-158
87. Manetto V, Abdul-Karim FW, Perry G, et al. Selective presence of ubiquitin in intracellular inclusions. Am J Pathology 1989 Mar; 134 (3): 505-513
88. Madhavan D, Kuzniecky RI. Lafora disease: reviews in neurological diseases. Rev Neurol Dis 2006 Summer; 3 (3): 131-135
89. Corkill RG, Hardie RJ. An unusual case of Lafora body disease. Eur J Neurol 1999 Mar; 6 (2): 245-247
90. Yoshimura I, Kaneko S, Yoshimura N, et al. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001 Sep; 46 (3): 283-287
91. Kyllerman M, Ben-Menachem E. Zonisamide for pro-gressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998 Jan; 29 (2): 109-114
92. GentonP,GelisseP, CrespelA.Lackof efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 2006 Dec; 47 (12): 2083-2085
93. de Quadros A, Sa DS, Kowacs PA, et al. Lafora's disease and movement disorders: report of 2 cases. Arq Neuro-psiquiatr 2000 Sep; 58 (3A): 720-723
94. Eldridge R, Iivanainen M, Stern R, et al. "Baltic" myo-clonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983 Oct 8; 2 (8354): 838-842
95. Miyahara A, Saito Y, Sugai K, et al. Reassessment of phenytoin for treatment of late stage progressive myo-clonus epilepsy complicated with status epilepticus. Epilepsy Res 2009 Mar 4; 84 (2-3): 201-209
96. Pranzatelli MR, Tate E, Huang Y, et al. Neuro-pharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-L-tryptophan. Epilepsia 1995 Aug; 36 (8): 783-791
97. Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neuro-surg Psychiatry 1998 Mar; 64 (3): 344-348
98. Fedi M, Reutens D, Dubeau F, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001 May; 58 (5): 781-786
99. Dias-Tosta E, Vieira LF, Alves A, et al. Lafora's disease: a possible diagnosis of juvenile dementia. Arq Neuro-psiquiatr 1995 Sep; 53 (3-A): 455-463
100. Delgado-Escueta AV, Bourgeois BF. Debate: does genetic information in humans help us treat patients? PRO-genetic information in humans helps us treat patients. CON-genetic information does not help at all. Epilepsia 2008 Dec; 49 Suppl. 9: 13-24
101. Canal-Sotelo J, Arraras-Torrelles N. Subcutaneous mid-azolam infusion and Lafora disease. Neurologia 2008 Jul-Aug; 23 (6): 396-397
102. Ben-Menachem E, Kyllerman M, Marklund S. Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res 2000 Jun; 40 (1): 33-39
103. Mervaala E, Andermann F, Quesney LF, et al. Common dopaminergic mechanism for epileptic photosensitivity in progressive myoclonus epilepsies. Neurology 1990 Jan; 40 (1): 53-56
104. Cardinali S, Canafoglia L, Bertoli S, et al. A pilot study of a ketogenic diet in patients with Lafora body disease. Epilepsy Res 2006 May; 69 (2): 129-134
105. Sugiyama H, Hainfellner JA, Lassmann H, et al. Un-common types of polyglucosan bodies in the human brain: distribution and relation to disease. Acta Neuro-pathologica 1993; 86 (5): 484-490
106. Mittal S, Dubey D, Yamakawa K, et al. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet 2007 Apr 1; 16 (7): 753-762
107. Vernia S, Rubio T, Heredia M, et al. Increased endo-plasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. PLoS One 2009; 4 (6): e5907
108. Castanheira P, Moreira S, Gama M, et al. Escherichia coli expression, refolding and characterization of human laforin. Protein Expr Purif Jun; 71 (2): 195-199
109. Gentry MS, Dixon JE, Worby CA. Lafora disease: insights into neurodegeneration from plant metabolism. Trends Biochem Sci 2009 Dec; 34 (12): 628-639
110. Ganesh S, Amano K, Delgado-Escueta AV, et al. Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A. Biochem Biophys Res Commun 1999 Apr 2; 257 (1): 24-28
111. Ganesh S, Delgado-Escueta AV, Sakamoto T, et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet 2002 May 15; 11 (11): 1251-1262
112. Raben N, Danon M, Lu N, et al. Surprises of genetic engineering: a possible model of polyglucosan body disease. Neurology 2001 Jun 26; 56 (12): 1739-1745
113. Puri R, Suzuki T, Yamakawa K, et al. Hyperphosphory-lation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem 2009 Aug 21; 284 (34): 22657-22663
114. Gredal H, Berendt M, Leifsson PS. Progressive myoclonus epilepsy in a beagle. J Small Anim Pract 2003 Nov; 44 (11): 511-514
115. Schoeman T, Williams J, van Wilpe E. Polyglucosan stor-age disease in a dog resembling Lafora's disease. J Vet Intern Med 2002 Mar-Apr; 16 (2): 201-207
116. Yamanami S, Ishihara T, Takahashi M, et al. Comparative study of intraneuronal polyglucosan bodies in brains from patients with Lafora disease and aged dogs. Acta Pathol Jpn 1992 Nov; 42 (11): 787-792
117. Kaiser E, Krauser K, Schwartz-Porsche D. Lafora disease (progressive myoclonic epilepsy) in the Bassett hound: possibility of early diagnosis using muscle biopsy? Tierarztl Prax 1991 Jun; 19 (3): 290-295
118. Jian Z, Alley MR, Cayzer J, et al. Lafora's disease in an epileptic Basset hound. NZ Vet J 1990 Jun; 38 (2): 75-79
119. Webb AA, McMillan C, Cullen CL, et al. Lafora disease as a cause of visually exacerbated myoclonic attacks in a dog. Can Vet J 2009 Sep; 50 (9): 963-967
120. Kamiya S, Suzuki Y. Polyglucosan bodies in the brain of the cat. J Comp Pathol 1989 Oct; 101 (3): 263-267
121. Hall DG, Steffens WL, Lassiter L. Lafora bodies asso-ciated with neurologic signs in a cat. Vet Pathol 1998 May; 35 (3): 218-220
122. Genton P. Lafora's disease (EPM2). Rev Neurol 2007 Jan; 163 (1): 47-53
123. Wright GD, McLellan DL. Absence of clinical or physio-logical changes during short-term cerebellar stimulation in a patient with Lafora body disease. J Neurol Neurosurg Psychiatry 1981 Apr; 44 (4): 364-366